Pasteurella Multocida Infection

Updated: Jul 26, 2022
Author: Sara L Cross, MD; Chief Editor: Michael Stuart Bronze, MD 

Overview

Background

Pasteurella multocida is a small, gram-negative, nonmotile, non–spore-forming coccobacillus with bipolar staining features. The bacteria typically appear as single bacilli on Gram stain; however, pairs and short chains also can be seen. P multocida often exists as a commensal in the upper respiratory tracts of many livestock, poultry, and domestic pet species, especially cats and dogs. In fact, Pasteurella species are some of the most prevalent commensal bacteria present in domestic and wild animals worldwide.[1, 2]  P multocida infection in humans often is associated with an animal bite, scratch, or lick, but infection without epidemiologic evidence of animal contact may occur.[1]  


Pasteurella multocida infection. Pasteurella multocida infection.

Wound infections associated with animal bites usually have a polymicrobial etiology, mandating the empiric use of broad-spectrum antimicrobials targeted at both aerobic and anaerobic gram-negative bacteria. Nevertheless, Pasteurella species commonly are isolated pathogens in most animal bites, especially in dog- and cat-related injuries. These injuries can be aggressive, with skin manifestations typically appearing within 24 hours after a bite. These wounds can exhibit a rapidly progressive soft-tissue inflammation that may resemble group A β-hemolytic Streptococcus pyogenes infections.

Deeper soft tissue also can be affected, manifesting as tenosynovitis, septic arthritis, and osteomyelitis. More-severe disseminating infections also may develop, including endocarditis or meningitis, the latter mimicking Haemophilus influenzae or Neisseria meningitides infections in young children. Fortunately, Pasteurella species are fairly sensitive organisms and can be treated with a penicillin-based regimen.[1]

Patients with P multocida infection who present without evidence of an animal bite are more likely to have invasive infection such as respiratory or bloodstream infection.[3]

Pathophysiology

Local:P multocida infection usually presents as an infection that complicates an animal bite or injury. Complications include rapidly progressive cellulitis, abscesses, tenosynovitis, osteomyelitis, and septic arthritis.[1, 4] The latter two are particularly common following cat bites because of their small, sharp, penetrative teeth.[5] Non-native septic arthritis also can occur.[6]

Respiratory:P multocida may cause upper respiratory tract infections, including sinusitis, otitis media, mastoiditis, epiglottitis,[7]  pharyngitis, and Ludwig's angina.[8] In rare cases, P multocida also may cause lower respiratory tract infections, including pneumonia, tracheobronchitis, lung abscess,[9] and empyema,[10] usually in individuals with underlying pulmonary disease.[1]

Cardiovascular:P multocida has been reported to cause native-[11] and prosthetic-valve endocarditis,[12] pericarditis, mycotic aneurysms,[13] vascular graft infections,[14] central venous catheter infections, bacteremia, sepsis, septic shock,[15] and disseminated intravascular coagulation.[16]

Central nervous system:P multocida is an uncommon cause of meningitis,[17]  subdural empyema, and brain abscess.[18]  P multocida meningitis has been associated with cat licks and bites occurring on the face in persons at the extremes of age.[19]

Gastrointestinal:P multocida rarely causes gastrointestinal problems but has been associated with appendicitis, hepatosplenic abscesses, and spontaneous bacterial peritonitis. P multocida has been isolated in patients with polymicrobial peritoneal dialysis catheter–associated peritonitis.[20]

Ocular:P multocida periocular abscess,[21] conjunctivitis, corneal ulcers, and endophthalmitis have been reported.

Genitourinary tract:P multocida pyelonephritis, renal abscess, epididymitis, and cervicitis have been reported in rare cases.

Epidemiology

Frequency

United States

According to the American Veterinary Medical Association, approximately 135 million dogs and cats live in the United States, and dogs currently outnumber cats by 19 million. Animal bites account for 1% (approximately 1 million) of annual emergency department visits. The estimated cost in health care expenditures is a reported $24 million per year. Approximately 10% of animal bites require medical attention; 1-2% eventually require hospitalization.

Approximately 5 million animal bites are reported annually. The vast majority of animal bites involve dogs (85-90%), followed by cats (5-10%).

Infectious complications occur in approximately 15-20% of dog-related bites and in more than 50% of cat-related ones. Dog bites are associated with younger animals engaging in playful activities, mostly with children. German shepherd, pit bull, Staffordshire terrier, and mixed breeds are most commonly involved with human bites, while the golden retriever and Labrador retriever are least. Cat bites are usually provoked, typically by female felines, and occur on the upper extremities or face. Sharp and long teeth of cats can easily penetrate human skin, creating a deep puncture wound and even inoculating the periosteum component of bones. Indeed, cat-related wounds more commonly progress to more serious and deeper-tissue infections, including osteomyelitis and meningitis.

International

P multocida infections occur worldwide. Cats are involved in 60-80% of human P multocida infections. Moreover, P multocida is isolated in 50% of dog bites.

Mortality/Morbidity

An estimated 10-20 human deaths per year occur following an animal bite.

Infectious complications occur in approximately 15-20% of dog-related bites and more than 50% of cat-related ones. After a bite, a rapidly progressive cellulitis may develop; deeper structures, including tendons, joints, and bones, can become affected, especially in cat-related injuries. Dissemination can occur.

Degenerative joint disease, rheumatoid arthritis, and prosthetic joints have been associated with the development of P multocida septic arthritis.[22]

Chronic obstructive pulmonary disease is a risk factor for P multocida respiratory tract infection,[23] which carries a mortality rate of approximately 30%. Diabetes mellitus[24] and liver dysfunction[25] are predisposing conditions associated with pasteurellosis and associated bacteremia.

P multocida infections during pregnancy and in utero transmission have also been reported.[26, 27, 28]

Localized P multocida infections carry an excellent prognosis. Significant morbidity has been associated with musculoskeletal P multocida infections, especially those involving the hand. Disseminated P multocida infections carry a 25-30% overall mortality risk.

Age

All age groups can be affected by P multocida infections. Young children seem to be frequently involved in nonfatal dog bites. P multocida meningitis typically occurs in persons at the extremes of age.

 

Presentation

History

A history of animal exposure, whether occupational or recreational, should alert the physician to the possibility of a zoonosis.[1, 29]

A detailed pet history, including exposure to pets owned by friends or strangers, should reveal the possibility of Pasteurella infection. However, cases of Pasteurella infection occur in the total absence of an epidemiologic link.

Physical

Physical findings of P multocida infection relate to the site of infection, as follows[1] :

  • Local - Erythema, warmth, pain and tenderness, purulent discharge, lymphangitis, joint swelling, decreased range of motion

  • Respiratory - Sinus tenderness, hoarseness, pharyngeal erythema, rales and rhonchi upon chest auscultation, dullness to percussion, changes in vocal fremitus

  • CNS - Focal neurologic deficits, signs of meningeal irritation (eg, nuchal rigidity, Brudzinski sign, Kernig sign)

  • Abdominal - Abdominal tenderness, guarding and rebound, hepatosplenomegaly, costovertebral angle tenderness

  • Ocular - Corneal ulcer, conjunctival injection, decreased visual acuity

  • Cardiovascular - Hypotension, tachycardia, new cardiac murmur, embolic phenomenon

  • Lymph nodes - Regional adenopathy

Causes

Causes of P multocida infection include the following[1] :

  • Dog bite or lick

  • Cat bite, lick, or scratch

  • Idiopathic (no history of pet exposure)

  • Immunosuppression

 

DDx

 

Workup

Laboratory Studies

Gram stain of purulent material or other fluid specimens including blood, sputum, and cerebrospinal fluid may show small, gram-negative, nonmotile, non–spore-forming pleomorphic coccobacilli.

Haemophilus species, N meningitides, Moraxella species, and Acinetobacter species have a morphology that is similar to that of P multocida infection and therefore can be easily confused with Pasteurella species.

Wright, Giemsa, and Wayson stains enhance bipolar staining. Some P multocida strains exhibit a mucous capsule.

The diagnosis is confirmed by identifying the organism in culture.

Pasteurella species are highly sensitive to several penicillins and cephalosporins. Susceptibility testing is indicated in immunocompromised patients and in the setting of treatment failure or drug allergies.

Imaging Studies

CT scanning and/or MRI: Evaluation of tenosynovitis, septic arthritis, osteomyelitis, and meningeal enhancement, when appropriate

Echocardiography: Evaluation of suspected endocarditis

Procedures

Deep soft-tissue P multocida infections require debridement at times. Intraoperative cultures should be taken at time of surgery.

Lumbar puncture should be performed if meningitis is suspected.

Arthrocentesis should be performed if septic arthritis is suspected.

Abdominal paracentesis is required in patients with ascites to assess the possibility of spontaneous bacterial peritonitis, especially in those with significant clinical liver disease with a history of pet exposure.

Histologic Findings

When available, infected tissue has features consistent with an acute purulent inflammation with neutrophilic predominance and possibly necrosis.

 

Treatment

Medical Care

Because P multocida infection mostly is encountered in the setting of an injury following an animal bite, physicians must be familiar with the associated microbiological oral flora of certain animals, especially dogs and cats.

Most animal bites are polymicrobial, with both aerobic and anaerobic bacteria. Several species can be isolated at once.

Several Pasteurella species are associated with dog and cat bites, including P multocida subspecies multocida,P multocida subspecies septica, Pasteurella stomatis, and Pasteurelladogmatis. Pasteurella canis is associated only with dog bites.

Other fastidious gram-negative organisms that have been associated with dog and cat bites include Capnocytophaga canimorsus and Capnocytophaga cynodegmi, especially in patients who had undergone previous splenectomy. C canimorsus infection can cause fulminant sepsis and meningitis, whereas C cynodegmi infection usually causes a milder localized inflammation.

Several other organisms are associated with cat bites, including Bartonella henselae, Francisella tularensis, and cowpox virus.

Medical management of animal bite wounds includes local wound care, standard-protocol tetanus prophylaxis, standard-protocol rabies prophylaxis, and either oral or intravenous empiric antimicrobial treatment.

Please see Medication for more detail about antimicrobial treatment.

Local care of bite wounds includes cleansing and removing nonviable tissue. Gently cleanse the skin surrounding the bite wound with an antiseptic solution. To prevent further tissue injury, do not scrub the wound directly. Soaking is of no benefit, but copious irrigation with a small-gauge catheter on a syringe helps remove debris and decreases the concentration of bacteria in contaminated wounds.

Please see Surgical Care for more detail about debridement and closure.

Surgical Care

The initial assessment of an animal bite includes an estimation of the infection risk. Bites to the head and neck, to the distal extremities, and near joints carry the highest risk for infection. In general, persons with animal bite wounds are at a high risk for infection, especially those who present to medical attention more than 8-10 hours after the injury occurred.

Persons with underlying medical diseases, such as diabetes mellitus, chronic liver disease, asplenia, alcoholism, HIV infection, or other immunodeficiency conditions (including chronic steroid exposure), are at increased risk for infection.

After irrigation and cleansing, sharply debride nonviable tissue to reduce the risk for infection and to allow easier suturing by providing a more even edge.

Primary suturing of bite wounds is reserved for minor injuries, those at low risk for infection, and those that have been treated within 8-10 hours of injury.

Leave all other wounds open until the risk for infection is reduced by cleansing, debridement, and prophylactic antibiotics.

Consultations

Consultations include the following:

  • General surgeon

  • Orthopedic surgeon

Activity

Elevation is of great importance in the management of limb injuries. Lack of elevation may result in excessive edema, which may produce compartment syndrome and compromise local circulation, to the extent of threatening the viability of the limb.

Wounds on extremities should be immobilized and elevated with a sling to reduce edema, which may hamper normal activities.

 

Medication

Medication Summary

Antimicrobial resistance among Pasteurella isolates rarely is reported in humans. Erythromycin, cephalexin and clindamycin most commonly are associated with resistance. Penicillin-resistance is rare; resistant strains have been isolated only from respiratory tract infections. Most animal-bite injuries can be treated with oral antimicrobials on an outpatient basis. Severe or partially responding infections may necessitate hospitalization and parenteral antimicrobial administration, along with surgical intervention.

Most Pasteurella isolates are susceptible to oral antimicrobials such as amoxicillin, amoxicillin/clavulanic acid, tetracyclines, fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin), and trimethoprim-sulfamethoxazole. Based on in vitro susceptibility data, several antimicrobials should not be used empirically for P multocida infections, including dicloxacillin, vancomycin, cephalexin, cefaclor, cefadroxil, erythromycin, and clindamycin. Macrolide resistance usually is encountered with erythromycin. Other macrolides, including azithromycin, clarithromycin, and telithromycin (in order of decreasing susceptibility), retain in vitro activity against most Pasteurella strains. Aminoglycosides have poor activity against P multocida.

More severe infections may require parenteral antibiotics. Intravenous ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin-tazobactam, cefoxitin, and carbapenems (imipenem-cilastatin, meropenem, ertapenem) are excellent empiric options for animal-bite injuries, providing gram-positive, gram-negative, and anaerobic coverage. The tetracycline-derivative tigecycline also has excellent in vitro activity against P multocida and other pathogens encountered in animal and bite injuries. If P multocida is the only isolated organism, therapy may be changed to intravenous penicillin G. Once clinical improvement is noted, oral penicillin VK is an option. Patients with penicillin allergies can receive minocycline, doxycycline, fluoroquinolones, trimethoprim-sulfamethoxazole, or azithromycin.

The duration of therapy for P multocida infection has not been well established and can be tailored to clinical response. Milder soft-tissue infections usually require 7-10 days of oral therapy. More severe cases can be treated for 10-14 days. Deep-tissue infections often require 4-6 weeks of treatment, and intravenous therapy may be indicated initially.

Antibiotics

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Amoxicillin and clavulanate (Augmentin)

Drug combination treats bacteria resistant to beta-lactam antibiotics. For children >3 mo, base dosing protocol on amoxicillin content. Because of different ratios of amoxicillin to clavulanic acid in 250-mg tab (250:125) vs 250-mg chewable tab (250:62.5), do not use 250-mg tab until child weighs >40 kg.

Cefuroxime (Ceftin, Zinacef)

Second-generation cephalosporin that maintains gram-positive activity of first-generation cephalosporins; adds activity against Proteus mirabilis, H influenzae, Escherichia coli, Klebsiella pneumoniae, and Moraxella catarrhalis. Condition of patient, severity of infection, and susceptibility of microorganism determine proper dose and route of administration.

Doxycycline (Vibra-Tabs, Bio-Tab, Doryx, Vibramycin)

Inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Penicillin G (Pfizerpen)

Inhibits biosynthesis of cell wall mucopeptide. Bactericidal against sensitive organisms when adequate concentrations are reached. Most effective during the stage of active multiplication. Inadequate concentrations may produce only bacteriostatic effects. Use penicillin VK for PO or penicillin G for IV.

Ampicillin and sulbactam (Unasyn)

Drug combination of beta-lactamase inhibitor with ampicillin. Covers skin, enteric flora, and anaerobes. Not ideal for nosocomial pathogens.

Ticarcillin and clavulanate (Timentin)

Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active growth. Antipseudomonal penicillin plus beta-lactamase inhibitor that provides coverage against most gram-positive organisms, most gram-negative organisms, and most anaerobes.

Ciprofloxacin (Cipro)

Mode of action of all quinolones involves inhibition of bacterial DNA synthesis by blocking the enzyme DNA gyrase

Amoxicillin (Trimox, Amoxil)

Interferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria.

Levofloxacin (Levaquin)

For pseudomonal infections and infections due to multidrug-resistant gram-negative organisms.

Ampicillin (Principen, Omnipen)

Bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take medication PO.

Piperacillin and tazobactam sodium (Zosyn)

Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active multiplication.

Ertapenem (Invanz)

Bactericidal activity results from inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin-binding proteins. Stable against hydrolysis by various beta-lactamases including penicillinases, cephalosporinases, and extended-spectrum beta-lactamases. Hydrolyzed by metallo-beta-lactamases.

Imipenem and cilastatin (Primaxin)

For treatment of multi-organism infections in which other agents do not have wide-spectrum coverage or are contraindicated because of potential for toxicity.

Minocycline (Dynacin, Minocin)

Treats infections caused by susceptible gram-negative and gram-positive organisms, in addition to infections caused by susceptible Chlamydia, Rickettsia, and Mycoplasma species.

Cefoxitin (Mefoxin)

Second-generation cephalosporin with activity against some gram-positive cocci, gram-negative rod infections, and anaerobic bacteria. Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits final transpeptidation step of peptidoglycan synthesis, resulting in cell wall death.

Infections caused by cephalosporin- or penicillin-resistant gram-negative bacteria may respond to cefoxitin.

Sulfamethoxazole and trimethoprim (Bactrim, Bactrim DS, Septra, Septra DS)

Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid.

Antibacterial activity of TMP-SMZ includes common urinary tract pathogens, except Pseudomonas aeruginosa.

Azithromycin (Zithromax)

Acts by binding to 50S ribosomal subunit of susceptible microorganisms and blocks dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Nucleic acid synthesis is not affected.

Concentrates in phagocytes and fibroblasts as demonstrated by in vitro incubation techniques. In vivo studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues.

Treats mild-to-moderate microbial infections.

Tigecycline (Tygacil)

A glycylcycline antibiotic that is structurally similar to tetracycline antibiotics. Inhibits bacterial protein translation by binding to 30S ribosomal subunit and blocks entry of amino-acyl tRNA molecules in ribosome A site. Complicated intra-abdominal infections caused by C freundii, E cloacae, E coli, K oxytoca, K pneumoniae, E faecalis (vancomycin-susceptible isolates only), S aureus (methicillin-susceptible isolates only), S anginosus group (includes S anginosus, S intermedius, and S constellatus), B fragilis, B thetaiotaomicron, B uniformis, B vulgatus, C perfringens, and P micros.

 

Follow-up

Further Outpatient Care

Careful follow-up evaluations of extensive bites or deep puncture wounds from cat bites are mandatory for early diagnosis of tenosynovitis, septic arthritis, and osteomyelitis.

Complications

Abscesses and tenosynovitis are the most common complications of P multocida soft-tissue infection. Septic arthritis and osteomyelitis are less common. CNS involvement with meningitis can occur. Dissemination is rare.

Prognosis

Soft-tissue P multocida infections carry an excellent prognosis. Deeper wounds, especially hand infections, may be associated with prolonged morbidity.

P multocida pulmonary infections, CNS involvement, bacteremia, and endocarditis carry a mortality rate of approximately 30%. Recent data show that patients presenting without evidence of an animal bite more frequently had respiratory and bloodstream infections and were relatively immunocompromised at baseline. These patients had a worse prognosis than patients with evidence of animal bite on presentation.[3]

Patient Education

For excellent patient education resources, visit eMedicineHealth's Infections Center. Also, see eMedicineHealth's patient education article Tetanus.

 

Questions & Answers

Overview

What is Pasteurella multocida infection?

What is the pathophysiology of Pasteurella multocida infection?

What is the incidence of Pasteurella multocida infection in the US?

What is the global incidence of Pasteurella multocida infection?

What is the mortality from of Pasteurella multocida infection?

What are possible complications of Pasteurella multocida infection?

What is the prognosis of Pasteurella multocida infection?

How does the incidence of Pasteurella multocida infection vary by age?

Presentation

What should be the focus of clinical history in evaluation for Pasteurella multocida infection?

Which physical findings are characteristic of Pasteurella multocida infection?

What are the causes of Pasteurella multocida infection?

DDX

What are the differential diagnoses for Pasteurella Multocida Infection?

Workup

What is the role of lab studies in the workup of Pasteurella multocida infection?

What is the role of imaging studies in the workup of Pasteurella multocida infection?

Which procedures are performed in the workup of Pasteurella multocida infection?

Which histologic findings are characteristic of Pasteurella multocida infection?

Treatment

Which bacteria species are associated with Pasteurella multocida infection?

What is included in the medical management for Pasteurella multocida infection?

What is the role of surgery in the treatment of Pasteurella multocida infection?

Which medical personnel may provide consultation to patients with Pasteurella multocida infection?

Which activity modifications are used in the treatment of Pasteurella multocida infection?

Medications

What is the efficacy of medications used in the treatment of Pasteurella multocida infection?

Which medications in the drug class Antibiotics are used in the treatment of Pasteurella Multocida Infection?

Follow-up

When is follow-up care needed for patients with Pasteurella multocida infection?

What are the complications of Pasteurella multocida infection?

What is the prognosis of Pasteurella multocida infection?

Where can patient education resources about Pasteurella multocida infection be found?